Investigational Drug Details
| Drug ID: | D245 |
| Drug Name: | Norursodeoxycholic acid |
| Synonyms: | 24-norursodeoxycholic acid; Nor-ursodeoxycholic acid; Norucholic acid; NorUrsodeoxycholic Acid |
| Type: | Chemical drug |
| DrugBank ID: | DB16260 |
| DrugBank Description: | norUrsodeoxycholic acid is under investigation in clinical trial NCT03872921 (Norursodeoxycholic Acid vs Placebo in PSC). |
| PubChem ID: | 192254 |
| CasNo: | 99697-24-2 |
| Repositioning for NAFLD: | No |
| SMILES: | C[C@]12[C@H]([C@H]3[C@H](CC2)[C@]2(C)[C@H](C[C@@H]3O)C[C@@H](CC2)O)CC[C@@H]1[C@@H](CC(=O)O)C |
| Structure: |
|
| InChiKey: | QYYDXDSPYPOWRO-JHMCBHKWSA-N |
| Molecular Weight: | 378.553 |
| DrugBank Targets: | -- |
| DrugBank MoA: | -- |
| DrugBank Pharmacology: | -- |
| DrugBank Indication: | -- |
| Targets: | -- |
| Therapeutic Category: | -- |
| Clinical Trial Progress: | Phase 2 on-going (EudraCT number 2013-004605-38: Norursodeoxycholic acid at 1500 mg resulted in a significant reduction of serum ALT within 12 weeks of treatment when compared with placebo. Norursodeoxycholic acid was safe and well tolerated encouraging further studies.) |
| Latest Progress: | Under clinical trials |
| Trial ID | Source ID | Phases | Status | Study Results | Start Date | Last Update Posted | |
|---|---|---|---|---|---|---|---|
| L0269 | NCT05083390 | Phase 2 | Recruiting | No Results Available | July 8, 2019 | October 27, 2021 | Details |
| L0476 | EUCTR2018-003443-31-CZ | Phase 2 | Authorised | No Results Available | 05/03/2019 | 2 March 2022 | Details |
| L0618 | EUCTR2013-004605-38-AT | Phase 2 | Not Recruiting | No Results Available | 02/12/2014 | 14 November 2016 | Details |
| Target ID | Target Name | GENE | Action | Class | UniProtKB ID | Entry Name |
|---|
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs |
|---|